Arrowhead gains EU authorisation for Redemplo in evolving FCS market

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve. EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve. Arrowhead’s authorisation of Redemplo without requiring genetic confirmation of FCS could facilitate access for a broader population of clinically diagnosed FCS patients and support market uptake. Credit: Piotr Swat via Shutterstock.com. Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor already approved in the US for the treatment of adults with familial chylomicronemia…

Source: Clinical Trials Arena